Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2

AGIOS PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$1.69 revenue$20,746,000

Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.
242 AQVESME prescriptions for thalassemia by U.S. REMS-certified physicians as of March 31, 2026.
Plans to submit mitapivat sNDA for sickle cell disease under accelerated approval pathway in Q2 2026.
Net loss $99.1M in Q1 2026 vs $89.3M in Q1 2025.
Cash and equivalents $1.0B as of March 31, 2026, down from $1.2B at Dec 31, 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGIOS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: net income $99.1 million.

Period: the quarter ended March 31, 2026
Net income: $99.1 million
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2026, net loss was $99.1 million, compared to net loss of $89.3 million for the quarter ended March 31, 2025.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-26-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.